Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30620404 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2GAALMNAKDM4ETBK1 | |
| SCHEMBL1032607 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1CYP1A2CYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL458310 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4590541 | 0.76 | ALDH1A1 (0.64) | SMN1; SMN2NPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL28975291 | 0.76 | NPC1 (0.59) | SMN1; SMN2NPC1CYP1A2CYP3A4CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL465775 | 0.75 | KCNJ1 (0.46) | SMN1; SMN2NPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL27099904 | 0.74 | OGA (0.65) | SMN1; SMN2OGA | |
| SCHEMBL470928 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12654042 | 0.74 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL29950392 | 0.74 | KDM4E (0.43) | NPC1KDM4ETBK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006504796-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | claimed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | claimed |
| EP-1551815-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | PFIZER INC | 2004-08-05 | — | — | US | disclosed |
| WO-2004033439-A1 | THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152747-A1 | Thiazole compounds for treatment of neurodegenerative disorders | APP, PARK7, IAPP | SMN1; SMN2 106/4885NPC1 83/4885CYP1A2 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.